Shifting focus to the topic of EGFR mutation, gefitinib was the first registered treatment with EGFR-TKI for lung cancer in 2009, specifically for EGFR mutation positive, locally advanced, and metastatic non-small cell lung cancer. This evidence concerns the gene EGFR and lung cancer.